Articles tagged with Clinical Trials
The Duke study aims to determine whether a modified form of the investigational bird flu vaccine can trigger a strong immune response at lower doses. The seven-month trial will test varying strengths of the H5N1 vaccine, either with or without an aluminum hydroxide adjuvant.
The H5N1 avian flu vaccine has shown promise in inducing immune responses in healthy adults. Among the 99 participants who received the high-dose vaccine, 54% developed neutralizing antibodies to the vaccine at a serum dilution of 1:40 or greater.
A study at Oregon Health & Science University found that stroke patients who received electrical stimulation therapy showed significant improvement in hand mobility and strength compared to those receiving rehabilitation alone. The therapy, which induces neural plasticity, helps patients regain lost functions.
A landmark trial found that carotid stenting significantly reduces the risk of stroke in asymptomatic patients with carotid artery disease, with a lower rate of major complications compared to medical therapy. The study also showed better outcomes for younger patients and no increased risk of undetected complications.
The MIST trial studied patients with severe, frequent migraines and a medium-to-large PFO, randomly assigning them to PFO closure or sham intervention. Results showed promise for PFO closure as a treatment option for relieving migraines.
The study demonstrates that carotid artery stenting with formalized training has outcomes comparable to the pivotal SAPPHIRE trial. Preliminary data indicates a low stroke rate of 3.6% at 30 days for patients treated by trained physicians.
A pilot study found valproic acid slows cognitive decline in HIV-related dementia, with potential applications for Alzheimer's and Parkinson's diseases. The treatment targets neuro-inflammation, a key factor in neurodegeneration.
Studies investigate homocysteine lowering and cardiovascular event rates, revealing high risks for patients with atherothrombosis. Researchers explore new treatment approaches, including bone marrow mobilization, to improve exercise capacity and prevent complications.
A multicenter trial found sirolimus-eluting stents to be more effective than vascular brachytherapy (VBT) in treating restenosis within a stent. The study showed significant differences in major adverse cardiac events, target lesion revascularization rates, and target vessel failure rates.
A large randomized trial of over 8,300 women with low dietary calcium found that calcium supplements significantly reduced severe preeclampsia, gestational hypertension, and preterm delivery. Calcium supplementation also led to a lower risk of maternal and neonatal morbidity and mortality.
Researchers at Yale are expanding a study using magnetic stimulation to treat schizophrenia, including a new trial with 90 patients. The treatment involves TMS, which modestly reduces the capacity of neurons to activate each other and may curb hallucinations.
Two Stanford University neurologists warn that clinical trials can be disastrous when a drug with unknown side effects is tested on healthy patients. They advocate for stricter entry criteria to prevent similar mistakes in the future.
A recent study found that stem cell mobilization therapy does not improve left ventricular recovery in patients with acute myocardial infarction. Despite significant mobilization of bone marrow stem cells, treatment did not alter infarct size or risk of restenosis or major adverse cardiac events.
Experts warn that sharing study results with participants could negatively impact their future health due to potential regret over less effective treatments. A revised informed consent strategy is proposed to balance individual rights with the need for transparency.
A recent study published in Anesthesiology found that xenon was administered safely to patients undergoing coronary artery bypass grafting, showing its potential as a neuroprotectant. The discovery could lead to new treatments for conditions such as strokes and brain injuries, where nerve damage is a major concern.
Researchers have successfully used pig islet cells to reverse type 1 diabetes in humans through transplantation. The demand for islet cells far outweighs the supply, but this breakthrough offers a potential solution. The University of Minnesota has made significant progress in developing a safe and reliable source of islet cells.
DePaoli asparagus offers a higher yield of spears than other varieties, reducing labor costs and making the vegetable more profitable. The new variety boasts an excellent spear quality, with a high percentage of marketable spears.
A study analyzing five clinical trials found that low-carbohydrate diets led to greater weight loss and improved HDL levels after six months. However, increased total cholesterol and LDL levels were observed in those on low-carb diets after a year.
A study led by Dr. Richard Goldberg found that the chemotherapy regimen FOLFOX4 is effective in treating colorectal cancer regardless of age, including older patients over 70. The analysis of nearly 4,000 patients showed consistent benefits and side effects across all age groups.
Researchers tracked over 8 years and found no reduction in colorectal cancer cases with low-fat diet intervention. The study suggests that mid-to-late life dietary changes may not significantly impact colorectal cancer risk.
A recent study published in JAMA Network found that a low-fat diet did not significantly decrease the risk of cardiovascular disease or stroke. However, trends toward greater reductions in CHD risk were observed in those with lower intakes of saturated fat or trans fat, or higher intakes of vegetables and fruits.
A human trial has shown that a ricin vaccine is safe and induces protective immunity in humans. The vaccine, called RiVax, produced neutralizing antibodies in all participants, even at the lowest dose tested.
A Phase 2 clinical study revealed that BiovaxID, a personalized anti-cancer vaccine, induced anti-tumor T-cell responses in most patients despite B-cell depletion. The overall survival rate was 89%, showing the vaccine's potential to treat other types of non-Hodgkin's lymphoma.
The Strategies for Management of Anti-Retroviral Therapy (SMART) trial found that participants on continuous antiretroviral therapy had significantly lower risk of disease progression compared to those on episodic therapy. The study also revealed increased risks of cardiovascular, kidney, and liver diseases in participants on the drug ...
A new clinical trials method is proposed to improve patient care by incorporating Bayesian approaches in trial design. The frequentist statistical method used today is considered too rigid and limits innovation, whereas the Bayesian approach allows for continuous updating based on interim results.
A meta-analysis of 36 clinical trials reveals that optimal radiation therapy significantly improves patient survival rates in breast cancer patients. The analysis found a 2.9% and 6.4% absolute increase in survival at 5 and 10 years, respectively.
A study of 13,041 cystic fibrosis patients found that those enrolled in clinical trials showed a slower decline in lung function compared to non-participants. The authors suggest that access to better healthcare through more office visits may be the key reason for this difference.
The Fluarix clinical study demonstrated the vaccine's ability to induce protective antibodies, making it a promising tool in bolstering flu vaccine supply. The successful collaboration between academia, industry, and government agencies enabled the rapid development of the vaccine.
The CYPHER Stent showed reduced restenosis and TLR rates compared to the Taxus stent. Exponential growth in 2005, driven by positive trial results, solidified its position as the leading drug-eluting stent globally.
A study found that informational campaigns alone may not be enough to increase participation in cancer clinical trials among black and Asian American patients. Lack of awareness about trial costs being covered by insurance is a significant barrier to participation, especially among those with lower incomes and education levels.
A Phase I clinical trial is underway to test the safety and potential of using child's own bone marrow stem cells to treat traumatic brain injury. The study aims to establish the safety of the procedure and observe possible therapeutic effects.
The International study reported a significant improvement in median time-to-disease progression with REVLIMID plus dexamethasone compared to placebo plus dexamethasone. The best response rate, complete response and near complete response rates were also higher with REVLIMID plus dexamethasone.
A study of lung cancer patients found that those who did not participate in clinical trials were more likely to be African American, female, or over 70. The researchers suggest targeting specific patient subgroups to improve representation in clinical trials.
A recent study published in The Lancet suggests that high-dose chemotherapy improves both event-free and overall survival for women with advanced breast cancer. This finding contradicts previous studies, highlighting the need for further investigation into this treatment strategy.
African-American women who joined a cancer screening trial had better understanding of cancer and early detection, motivated by loved one's experience with cancer. The study suggests targeted strategies to improve recruitment, including providing health benefits and informing physicians about clinical trials.
A nationwide randomized clinical trial found that mycophenolate mofetil produced fewer complications than the standard medication Cytoxan in patients with lupus nephritis. The study showed that oral mycophenolate mofetil worked faster in relieving inflamed kidneys and improved patient outcomes.
Patients who received left ventricular assistant devices (LVADs) had a significantly longer average survival time of 10.3 months compared to 3.1 months without the device. The study found that 78% of patients died within six months and 90% within a year without LVAD support.
Researchers reported that most volunteers developed strong, specific, and long-lasting immune responses to the MSP3 protein after vaccination. The vaccine also demonstrated functional antibody responses that could inhibit malaria parasite growth in laboratory assays.
A Phase III trial demonstrated a significant increase in average time to progression with sunitinib treatment compared to placebo, leading to improved overall survival. Treatment with sunitinib was well-tolerated, with common side effects including fatigue and diarrhoea.
The new Clinical Trials Directive has led to differences in the scope of revised legislations across EU member states, with only a few adding provisions for non-commercial trials. The directive also simplifies the conduct of academic clinical trials but poses challenges for future pan-European multi-centre studies.
A Dutch study found that higher doses of radiotherapy significantly improved patient outcome over a five-year period. An anti-androgen therapy trial suggested early treatment can benefit locally advanced disease, while immunotherapy trials are showing promising results for androgen-independent prostate cancer.
A review of 143 clinical trials that were stopped early due to benefits found many were industry-funded drug trials with high-impact journals. The proportion of such trials increased over time, often with implausibly large treatment effects, suggesting skepticism from physicians.
A novel probiotic strain, B. infantis 35625, shows promise in normalizing bowel movement frequency in IBS patients. Researchers found modest improvement in bloating symptoms, but emphasize the need for larger trials to verify findings.
A new study introduces a Clinical Trial Alert (CTA) system that leverages electronic medical record capabilities to increase patient referrals and enrollment rates. The system significantly improved physician referrals and patient enrollments, doubling the study's enrollment rate from physician referrals.
A double-blind, placebo-controlled study found that COLD-fX significantly reduced upper respiratory infections by 25% and recurrent infections by 56%. The treatment also showed a significant effect in reducing symptom scores and infection duration.
Patients taking ASA plus dipyridamole had increased rates of myocardial infarction, but the addition of dipyridamole is rarely justified for stroke prevention. ASA remains the gold standard treatment for preventing stroke in high-risk patients.
A clinical trial alert system significantly increased physicians' participation in patient recruitment, doubling the enrollment rate from 2.9 to 6.0 participants per month. The system alerted physicians about ongoing trials when a patient's records met selected criteria, leading to a 10-fold increase in referrals.
A new study found that drug-eluting stents like CYPHER are cheaper than open-heart surgery, saving patients and the healthcare system $6,487 on average over a year. The research also shows improved patient outcomes with stent treatment.
The Mayo Clinic report reveals that trastuzumab is the most effective treatment for women with HER2-positive breast cancer. With a disease-free rate of 90.4% at three years, this breakthrough offers new hope to millions of women worldwide affected by this type of cancer.
The SAPPHIRE and US carotid feasibility trials demonstrated the durability of carotid stenting, showing low incidence of stroke and comparable target lesion revascularization (TLR) rates between CAS and CEA. Emboli protection with ANGIOGUARD also showed effectiveness in preventing major strokes during carotid stenting.
The PRISON II trial found that CYPHER Stent patients experienced lower rates of in-stent restenosis and target vessel failure compared to bare metal stents. This study provides new clinical evidence for the use of CYPHER Stent in complex patient cases.
Researchers have found that combining the monoclonal antibody C225 with photodynamic therapy in a mouse model of ovarian cancer resulted in substantial tumor reduction and improved survival rates compared to single-agent treatments. This innovative approach may provide new hope for women diagnosed with this aggressive form of cancer.
A joint project between Cyberkinetics, Case Western Reserve University, and the Cleveland FES Center aims to develop a neuroprosthetic system capable of restoring partial arm and hand function. The proposed system combines limb movement technology with brain-interface technology to enable human users to control devices through thought ...
Researchers analyzed data from a large trial and found no safety concerns for patients with very low LDL levels. The study suggests that intensive statin therapy may be beneficial even when LDL levels drop below targeted levels.
A moderate exercise regimen, equivalent to 12 miles of brisk walking per week, can significantly improve fitness levels and reduce cardiovascular disease risks. The study found that even slight increases in intensity or duration yield greater health benefits.
Researchers at the University of Manchester have shown that IL-1ra protects brain cells from injury and death in laboratory studies. The first small trial of IL-1ra in patients has demonstrated promising results, which may lead to a full trial next year to test its effectiveness.
Researchers found that ICDs provide value in appropriate patients, but more research is needed to identify high-risk patients who would benefit most from the therapy. The study suggests that ICD use could be more cost-effective with lower implantation costs or extended device lifespan.
A randomized controlled trial found that therapy guided by pulmonary artery catheter monitoring did not improve survival or reduce hospital stays for patients with severe heart failure. However, the study suggests that PAC monitoring may be beneficial for patients who do not respond to initial therapy.
The updated data show that 51% of patients originally assigned to the Betaseron 250 mcg group can walk with or without assistance, compared to 45% in the placebo group. Additionally, 95% of patients in the Betaseron 250 mcg group are still alive after 16 years, compared to 83% in the placebo group.
The Phase I trial demonstrated the treatment's safety and efficacy in advanced Parkinson's disease, with statistically significant improvements in motor function and activities of daily living. The gene therapy approach offers a simpler alternative to deep brain stimulation, avoiding devices and requiring local anesthesia.